Papers/PMID:28241817
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
BMC endocrine disorders2017The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
berberine — decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3“After the 16-week BBR intervention, the NAFLD + BBR group (736 ± 20.80) exhibited a significant reduction in body weight compared with the NAFLD group (828.67 ± 86.78) (P < 0.05, Fig. 3a).”
Quoted verbatim from Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.. - Study
- animal · not in humans
- Dose
- 150 mg/kg body weight per day by gavage for 16 weeks
- Population
- Male Sprague-Dawley rats with high-fat-diet-induced non-alcoholic fatty liver disease; berberine versus normal-saline gavage, body weight at end of 16-week intervention
Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.2017PMID:28241817Permalink